Table 1.
Baseline characteristics in LV remodeling and non LV remodeling groups.
| Variables | LVR(+), n = 24 | LVR(-), n = 73 | P |
|---|---|---|---|
| Age Male |
65.5 ± 12.0 19 (79.2%) |
59.8 ± 12.4 67 (91.8%) |
0.050 0.091 |
| Body surface area (m2) | 1.7 ± 0.2 | 1.8 ± 0.2 | 0.501 |
| Body mass index (kg/m2) | 24.7 ± 3.9 | 25.2 ± 3.7 | 0.602 |
| Systolic blood pressure (mmHg) | 153.5± 26.8 | 157.3± 29.9 | 0.577 |
| Heart rate (bpm) | 74.8 ± 19.4 | 73.9 ± 16.1 | 0.814 |
| D-to-B (hour) | 7.8 ± 18.1 | 20.4 ± 30.6 | 0.018 |
| S-to-B (hour) | 13.6 ± 22.3 | 29.1 ± 35.0 | 0.015 |
| STEMI | 17 (70.8%) | 42 (57.5%) | 0.247 |
| Hypertension | 14 (58.3%) | 43 (58.9%) | 0.961 |
| Diabetes mellitus | 7 (29.2%) | 21 (28.8%) | 0.970 |
| Smoking | 12 (50.0%) | 43 (58.9%) | 0.445 |
| Coronary artery disease history | 0 (0%) | 6 (8.2%) | 0.147 |
| Chronic obstructive pulmonary disease | 0 (0%) | 3 (4.1%) | 0.313 |
| Peripheral vascular disease | 1 (4.2%) | 1 (1.4%) | 0.403 |
| Old stroke | 0 (0%) | 4 (5.5%) | 0.242 |
| Hyperlipidemia | 8 (33.3%) | 25 (34.2%) | 0.935 |
| Renal insufficiency | 2 (8.3%) | 4 (5.5%) | 0.615 |
| Moderate-to-severe MR | 0 (0 %) | 2 (2.9%) | 0.445 |
| Medication | |||
| ACEI or ARB | 9 (37.5%) | 33 (45.2%) | 0.509 |
| Beta-blocker | 15 (62.5%) | 37 (50.7%) | 0.314 |
| Statin | 16 (66.7%) | 52 (71.2%) | 0.672 |
| Diuretic | 0 (0%) | 0 (0%) | NA |
| Aldactone | 0 (0%) | 0 (0%) | NA |
D-to-B: door-to-balloon time; S-to-B: symptom-onset-to-balloon time; STEMI: ST-segment elevation myocardial infarction; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; MR: mitral regurgitation; NA: non-assessment.